Given the well-documented association between chronic inflammation, insulin resistance, and cancer risk, GLP-1’s capacity to modulate inflammatory pathways positions it as a promising molecule with potential oncoprotective properties. This evidence concerns the gene GLP1R and Insulin resistance.